The Lanham Act and the FD&C Act: Shaping the Law of False Advertising into a Tool for Drug Manufacturers to Self-Regulate Their Industry and Protect Consumers

DSpace/Manakin Repository

The Lanham Act and the FD&C Act: Shaping the Law of False Advertising into a Tool for Drug Manufacturers to Self-Regulate Their Industry and Protect Consumers

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Turko, Jessica en_US
dc.date.accessioned 2012-06-15T20:20:44Z
dc.date.issued 2001 en_US
dc.identifier.citation The Lanham Act and the FD&C Act: Shaping the Law of False Advertising into a Tool for Drug Manufacturers to Self-Regulate Their Industry and Protect Consumers (2001 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8889455
dc.description.abstract While Section 43(a) of the Lanham Act has the potential to become an extremely useful tool to ensure competitive fairness and consumer safety in the pharmaceutical industry, recent cases show that numerous obstacles prevent Lanham Act plaintiffs from prevailing in their lawsuits. In this Paper, I will examine how the procedural requirements of false advertising law and substantive FDA doctrines combine to hinder drug manufacturer-plaintiffs’ chances for success in Lanham Act claims. I will advocate greater clarification of the evidentiary standards and standing requirements for Lanham Act claims and suggest reforms for FDA’s regulations regarding manufacturers of generic drugs and foreign manufacturers whose drugs are not approved for use in the United States. I will describe the elements necessary for a successful claim under the Lanham Act using the recent case of Zeneca, Inc. v. Eli Lilly & Co., 1999 U.S. Dist. LEXIS 10852 (S.D.N.Y. July 19, 1999) as an example. Finally, I will explore alternatives to private litigation for false advertising cases, including trademark infringement litigation, lawsuits initiated by FDA and the Federal Trade Commission (“FTCâ€), and suits by state attorneys general. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject Lanham Act en
dc.subject FDCA en
dc.subject false advertising en
dc.subject consumer en
dc.title The Lanham Act and the FD&C Act: Shaping the Law of False Advertising into a Tool for Drug Manufacturers to Self-Regulate Their Industry and Protect Consumers en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-15T20:20:44Z

Files in this item

Files Size Format View
Turko.rtf 177.8Kb RTF file View/Open
Turko.html 152.1Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters